Status:

COMPLETED

Retinal Metabolic Imaging of Alzheimer Patient

Lead Sponsor:

Optina Diagnostics Inc.

Collaborating Sponsors:

McGill University

Sunnybrook Health Sciences Centre

Conditions:

Alzheimer Disease

Eligibility:

All Genders

50-90 years

Phase:

NA

Brief Summary

This research project concerns the evaluation of the Metabolic Hyperspectral Retinal Camera (MHRC), a novel medical instrument from Optina Diagnostics, for the detection of beta-amyloid plaques, a hal...

Detailed Description

Alzheimer's disease (AD), a neurodegenerative disorder characterized by cognitive impairment and a suspected dementia syndrome, is the most common type of dementia (\>50% of all cases), affecting mill...

Eligibility Criteria

Inclusion

  • Subjects with Alzheimer's disease
  • Meet criteria for probable, possible Alzheimer's disease by McKhann criteria (McKhann et al. 2011)
  • Mini-Mental State Examination score between 20 and 27 (inclusive)
  • Vascular load scale ≤ 4 (Hachinski Ischaemia Score)
  • Sufficient degree of cooperation to undergo all examinations
  • Availability of a reliable responsible study partner to accompany the patient to the appointments
  • Subjects with Mild Cognitive Impairment
  • Meet criteria for amnestic single or multi domain Mild Cognitive Impairment (without crossing the threshold for dementia)
  • No signs of systemic, neurologic or psychiatric disorders that can cause cognitive deficits
  • Scores on cognitive tests: 1 to 1.5 standard deviation below the mean of their age and education matched peers
  • Diagnosis that follows Albert criteria (Albert et al. 2011)
  • Healthy control subjects
  • No clinical signs of dementia
  • Telephone Mini-Mental State Examination score ≥ 25 or
  • MoCA ≥ 26
  • Behavioural Neurology Assessment-R (BNA-R; Annex IX; within limits on all sub tests)

Exclusion

  • Presence of one or more contraindications (PET and/or MRI)
  • Presence of glaucoma or retinopathy (diabetic, macular degeneration)
  • Pupil dilation inadequate or contraindicated
  • Deficient visual fixation
  • Refractive error outside the range -9 to +9
  • Impossibility of obtaining satisfactory, quality images with MHRC

Key Trial Info

Start Date :

December 4 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 12 2020

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT03420807

Start Date

December 4 2017

End Date

March 12 2020

Last Update

March 28 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada, M4N 3M5